The overall goal of this program project grant (PPG) continues to be the exploration of the cellular and molecular mechanisms of allogeneic bone marrow transplantation (BMT) and to serve as a translational research platform for novel therapeutic strategies for patients with hematologic malignancies. Graft versus host disease (GVHD) remains a major cause of morbility and mortality after allogeneic BMT and prevents this curative therapy from wider application in cancer patients;thus a long term goal for the entire area of BMT is to develop new strategies to separate a beneficial graft versus leukemia (GVL) effect from GVHD. This PPG contributes to that goal by: 1) exploring the cellular and molecular mechanisms of GVHD from several perspectives;and 2) functioning as a translational research platform for the application of these mechanistic insights in Phase l/ll clinical trials in BMT patients. The significance of these studies therefore lies in their potential to lead to novel therapies for cancer patients, particularly those with hematologic malignancies. The major theme of this PPG is the modulation of donor immune responses to allogeneic host tissues without removal of T cells from the donor graft. This theme of modulating the interactions among the cellular subpopulations that initiate and mediate GVHD develops in several ways and unifies the entire PPG increasing collaborations and interactions among project leaders and provides multiple opportunities for synergy. In this next cycle, the PPG components continue as three projects and three cores: Project 1 HDAC Inhibition to Prevent GVHD Project 2 A Novel Bioenergetic Strategy to Treat GVHD Project 3 GVHD Clinical Trials and Biomarkers Core A Administration and Biostatistics Core B Experimental BMT Core C Clinical Sample Database and Proteomics

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA039542-26
Application #
8545536
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Program Officer
Merritt, William D
Project Start
1997-09-10
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
26
Fiscal Year
2013
Total Cost
$1,558,878
Indirect Cost
$524,630
Name
University of Michigan Ann Arbor
Department
Pediatrics
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Curry Jr, William T; Gorrepati, Ramana; Piesche, Matthias et al. (2016) Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res 22:2885-96
Kitko, Carrie L; Braun, Thomas; Couriel, Daniel R et al. (2016) Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant 22:862-8
Harris, Andrew C; Young, Rachel; Devine, Steven et al. (2016) International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22:4-10
Renteria, Anne S; Levine, John E; Ferrara, James L (2016) Development of a biomarker scoring system for use in graft-versus-host disease. Biomark Med 10:793-5
Abedin, Sameem; Yanik, Gregory A; Braun, Thomas et al. (2015) Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant 21:1127-31
Chiaranunt, Pailin; Ferrara, James L M; Byersdorfer, Craig A (2015) Rethinking the paradigm: How comparative studies on fatty acid oxidation inform our understanding of T cell metabolism. Mol Immunol 68:564-74
Levine, John E; Braun, Thomas M; Harris, Andrew C et al. (2015) A PROGNOSTIC SCORE FOR ACUTE GRAFT-VERSUS-HOST DISEASE BASED ON BIOMARKERS: A MULTICENTER STUDY. Lancet Haematol 2:e21-e29
Levine, John E; Braun, Thomas M; Harris, Andrew C et al. (2015) A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2:e21-9
Tkachev, Victor; Goodell, Stefanie; Opipari, Anthony W et al. (2015) Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol 194:5789-800
Levine, John E; Hogan, William J; Harris, Andrew C et al. (2014) Improved accuracy of acute graft-versus-host disease staging among multiple centers. Best Pract Res Clin Haematol 27:283-7

Showing the most recent 10 out of 219 publications